(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Telescope in Chile captures stunning new picture of a cosmic butterfly - 2This star-forming galaxy is blowing out powerful winds topping 2 million mph
- 3I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- 4Ober Gabelhorn glacier reveals remains of man missing for over three decades
- 5'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- UK, Canada, Germany, others condemn Israel's West Bank settlement plan
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Embracing Practical Living and Ecological Protection
- Israeli lawmakers pass bill reviving death penalty for terrorists
- NASA is shooting for the moon. A guide to the Artemis II mission
- High Court freezes government move to shutter Army Radio pending ruling
- Cathay Pacific raises fuel surcharge on all flights by 34%
- Figure out how to Arrange a Fair Settlement with the Assistance of a Fender bender Legal counselor
- Iranian-backed militias escalate in Iraq, targeting Kurdistan Region president Nechirvan Barzani
